No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan.
about
CYP17 genetic polymorphism, breast cancer, and breast cancer risk factorsVariants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association studyCYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control studyCYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.CYP17 and breast cancer: no overall effect, but what about interactions?CYP17 gene polymorphism in relation to breast cancer risk: a case-control studyThe role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast.Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis.Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer.Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer.Association between CYP17 T-34C rs743572 and breast cancer risk.Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping.Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women
P2860
Q24795469-016CF518-D7CD-415B-82EF-5C13DC9BDA93Q24796616-8335A46D-6D50-4829-B531-16EF80BD48DEQ24810611-B63DBC74-9F86-4932-8FFB-4AFDDC1868F2Q24810733-C5587DCD-2980-48AF-87EE-2088D599BB92Q25257341-22E3A1E7-A55F-4022-A9A1-B04D0DB24A75Q25257428-16D18284-3303-4F3C-ABCB-053A79AFFF4DQ34291721-8E7D84C3-954C-4C9C-95CC-3E01D7A082DDQ37665345-BF21EECE-8B37-471B-AF99-C65B17461CF1Q38347647-75C26D78-FBD2-4B6F-8C83-F75CE0FBEB4FQ39213223-E88FB8F8-C742-4F43-996A-22CA4A237ADAQ48018693-36292598-0193-4F5D-8C36-871852A36785Q49163775-A3EFCC3C-CCF6-4F13-B5BE-F2F22BC6AE21Q54936056-AF45B906-058C-4E82-A0AF-9D3C7923B0BCQ57919038-2A1C8D51-523B-4F38-B813-52C066256740
P2860
No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
No association of the 5' promo ...... h breast cancer risk in Japan.
@en
No association of the 5' promo ...... h breast cancer risk in Japan.
@nl
type
label
No association of the 5' promo ...... h breast cancer risk in Japan.
@en
No association of the 5' promo ...... h breast cancer risk in Japan.
@nl
prefLabel
No association of the 5' promo ...... h breast cancer risk in Japan.
@en
No association of the 5' promo ...... h breast cancer risk in Japan.
@nl
P2093
P2860
P1476
No association of the 5' promo ...... h breast cancer risk in Japan.
@en
P2093
M Mizutani
N Hamajima
P2860
P304
P356
10.1111/J.1349-7006.2000.TB01029.X
P577
2000-09-01T00:00:00Z